Kidney Week

Educational Symposium

Autosomal Dominant Polycystic Kidney Disease: Risk Assessment and Management

October 22, 2020 | 01:00 PM - 02:00 PM

Location: Simulive

Session Description

ADPKD, the most common monogenic cause of kidney failure in humans, primarily caused by mutations of PKD1 or PKD2, which encode the proteins polycystin 1 and polycystin 2, respectively. Progression of ADPKD can be highly variable. Age, eGFR, and total kidney volume are factors used to predict the risk of disease progression.

Measures that slow the progression of ADPKD include controlling blood pressure, particularly with the use of ACE inhibitors or ARBs, maintaining sufficient hydration, and treating urinary tract infections and, for patients whose kidney disease is rapidly progressing, taking tolvaptan.

This symposium provides updates about assessing symptoms and risk in patients with ADPKD and reviews the management of renal and nonrenal complications.

Support is provided by an educational grant from Otsuka America Pharmaceutical, Inc.

Learning Objective(s)

• Describe the risk of progression in individuals with ADPKD
• Discuss current best practices in the pharmacological and non-pharmacological management of ADPKD

Learning Pathway(s)

• Genetic Diseases of the Kidneys

Moderator

• Fouad T. Chebib, MD, FASN

Presentations

• Introduction
  01:00 PM - 01:10 PM
  Fouad T. Chebib, MD, FASN 
  
  

  Fouad T. Chebib, MD, FASN

  Dr. Fouad T. Chebib, MD, FASN is a nephrologist and Assistant Professor of Medicine at Mayo Clinic, Rochester, MN, USA. His clinical and research focus is advancing the medical care and preventing kidney failure in patients with Polycystic Kidney Disease. He has participated in several clinical trials with novel therapeutics for ADPKD patients and helped develop a practical guide in treating ADPKD patients with disease-modifying treatments. His research examines molecular mechanisms that lead to cyst formation on ADPKD patients and explores targeted treatment options. He is also leading innovative projects in delivering medical care to ADPKD patients globally.

Introduction

October 22, 2020 | 01:00 PM - 01:10 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Assessing Symptoms and Risks in ADPKD
  01:10 PM - 01:35 PM
  Ron T. Gansevoort, MD, PhD, FASN 
  
  

  Ron T. Gansevoort, MD, PhD, FASN

  Ron Gansevoort is professor of Medicine and practicing nephrologist, at the Dept. of Nephrology at the University Medical Center Groningen, the Netherlands. He has two lines of research: the epidemiology of chronic kidney disease (CKD) and prevention of renal function loss in patients with heritable polycystic kidney disease (PKD). He heads the Groningen Expertise Centre for PKD. He was/is member of the Steering Committee of several international randomised controlled clinical trials in the field of PKD (TEMPO 3:4, TEMPO 4:4, REPRISE, DIPAK-1, STAGED-PKD, MANGROVE), as well as diabetic nephropathy (ARTS-DN, FIDELIO, FIGARO, CONCORD). Prof. Gansevoort is member of the Council of the Dutch and European Renal Associations, associate editor for 5 nephrological journals and (co)authored over 500 peer-reviewed papers.

Assessing Symptoms and Risks in ADPKD

October 22, 2020 | 01:10 PM - 01:35 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Current Best Practices in the Management of ADPKD
  01:35 PM - 02:00 PM
  Ronald D. Perrone, MD, FASN 
  
  

  Ronald D. Perrone, MD, FASN

  I have had a long-standing and wide-ranging interest in ADPKD, including basic investigations addressing mechanisms of ion transport by cystic epithelia, clinical investigations describing causes of mortality in the ADPKD ESRD population, and participation and direction of clinical trials in ADPKD. I have participated in all of the major clinical trials in ADPKD serving as the Boston site Principal Investigator and member of the Steering Committees for the HALT PKD study, the TEMPO 3/4 and REPRISE trials of tolvaptan in ADPKD, the TAME-PKD study of metformin, and the Venglustat STAGED-PKD study. I also serve as Boston site PI for the Tesevatinib and Bardoxolone (Falcon) studies. I have been a member of the Scientific Advisory Committee of the Polycystic Kidney Disease Foundation from 1999 to 2017 (Chairman from 2006-2010). I served as Co-Investigator with Dr. Andrew Levey in the pilot and planning phases (Phase I and II) of the Modification of Diet in Renal Disease (MDRD) study and played a fundamental role in the validation and use of the 125I-iothalamate protocol used for the MDRD and other clinical trials of progressive kidney disease. Over the past 10 years, I initiated and co-led the PKD Outcomes Consortium and have been the principal individual involved in bringing together the contributors from academia, pharma, NIH, FDA, EMA, CDISC, and C-Path. Total kidney volume has recently been approved as a prognostic biomarker by both the FDA and the EMA.

Current Best Practices in the Management of ADPKD

October 22, 2020 | 01:35 PM - 02:00 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.